Table 5.

Predicted cumulative incidence of complications associated with 534 and 729 A1c Months in the DCCT-eligible subgroup of the EDC cohort compared with the reported cumulative incidence in the DCCT/EDIC intensive and conventional treatment groups at 20 years’ diabetes duration

	DCCT treatment group
	Conventional (n = 730)	Intensive (n = 711)	RRR (95% CI)
A1c Months	729	534
Proliferative retinopathy
EDC predicted, based on A1c Months	20.5%	10.7%	48% (32, 59)
DCCT/EDIC reported, 20 years	18%	7%	61% (47, 71)
Overt nephropathy
EDC predicted, based on A1c Months	6.1%	2.8%	54% (24, 73)
DCCT/EDIC reported, 20 years	12%	4%	67% (51, 78)
CVD
EDC predicted, based on A1c Months	8.2%	4.8%	41% (13, 61)
DCCT/EDIC reported, 20 years	5%	3%	40% (0, 65)